Eli Lilly’s Q3 2026 Mounjaro sales will be reported alongside full quarterly results on October 29, 2026, following Q2 revenue of $9.94 billion that reflected 91% year-over-year growth and a 60% volume increase despite a 13% decline in realized prices. Continued momentum stems from expanded supply, rising U.S. prescriptions, international revenue acceleration (now exceeding domestic in recent quarters), and broader Medicare GLP-1 coverage, though tempered by competitive pressure from oral alternatives and ongoing net price erosion. Analyst models project U.S. Mounjaro sales near $5 billion for the quarter, consistent with the company’s raised full-year 2026 revenue guidance of $85–87 billion. Market-implied odds in related prediction markets will reflect how closely actual results align with these consensus figures and any commentary on fourth-quarter trajectory.